Literature DB >> 22920178

miRNAs as mediators of drug resistance.

Sierk Haenisch1, Ingolf Cascorbi.   

Abstract

Chemoresistance of tumors is often reported to be due to overexpression of efflux transporters or genetic alterations of signaling pathways. More recently, there is increasing evidence that epigenetic modification contributes to the phenomenon of drug resistance. Despite alteration of DNA methylation or histone modifications, deregulated miRNA expression patterns of tumor cells have been identified as interfering with drug response. Attempts to modify the expression of selected miRNAs have partly led to intriguing improvements of chemotherapy response. This review focuses on the major epigenetic mechanisms, including the role of miRNA expression contributing to drug resistance and the role of epigenetic drugs to overcome nonresponse arising under conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920178     DOI: 10.2217/epi.12.39

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  28 in total

1.  Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.

Authors:  Edward A Ratovitski
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

2.  Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.

Authors:  Yolande Berthois; Christine Delfino; Philippe Metellus; Frederic Fina; Isabelle Nanni-Metellus; Hayat Al Aswy; Victor Pirisi; L'Houcine Ouafik; Françoise Boudouresque
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

Review 3.  Challenges in pharmacogenetics.

Authors:  Ingolf Cascorbi; Oliver Bruhn; Anneke N Werk
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 4.  MicroRNAs and their relevance to ABC transporters.

Authors:  Sierk Haenisch; Anneke Nina Werk; Ingolf Cascorbi
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 5.  Oxidative stress in bladder cancer: an ally or an enemy?

Authors:  Fernando Mendes; Eurico Pereira; Diana Martins; Edgar Tavares-Silva; Ana Salomé Pires; Ana Margarida Abrantes; Arnaldo Figueiredo; Maria Filomena Botelho
Journal:  Mol Biol Rep       Date:  2021-03-17       Impact factor: 2.316

Review 6.  Long noncoding RNA HOTAIR involvement in cancer.

Authors:  Yansheng Wu; Li Zhang; Yang Wang; Hui Li; Xiubao Ren; Feng Wei; Wenwen Yu; Xudong Wang; Lun Zhang; Jinpu Yu; Xishan Hao
Journal:  Tumour Biol       Date:  2014-08-29

7.  miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.

Authors:  A A Takwi; Y-M Wang; J Wu; M Michaelis; J Cinatl; T Chen
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

Review 8.  Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.

Authors:  Ramón Cacabelos; Clara Torrellas
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

9.  miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

Authors:  Jing Sun; Xin Cai; Mingo Mh Yung; Wei Zhou; Jing Li; Yi Zhang; Zhuqing Li; Stephanie S Liu; Annie N Y Cheung; Hextan Y S Ngan; Yiliang Li; Zhijun Dai; Yan Kai; Alexandros Tzatsos; Weiqun Peng; David W Chan; Wenge Zhu
Journal:  Oncogene       Date:  2018-08-30       Impact factor: 9.867

10.  MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells.

Authors:  Qing Hu; Wei-xian Chen; Shan-liang Zhong; Jun-ying Zhang; Teng-fei Ma; Hao Ji; Meng-meng Lv; Jin-hai Tang; Jian-hua Zhao
Journal:  Tumour Biol       Date:  2014-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.